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Abstract
Background: Parental age has been associated with several childhood cancers, albeit the 
evidence is still inconsistent.
Aim: To examine the associations of parental age at birth with acute myeloid leukemia (AML) 
among children aged 0-14 years using individual-level data from the Childhood Leukemia 
International Consortium (CLIC) and non-CLIC studies.
Material/Methods: We analyzed data of 3182 incident AML cases and 8377 controls from 17 
studies [seven registry-based case-control (RCC) studies and ten questionnaire-based case-control 
(QCC) studies]. AML risk in association with parental age was calculated using multiple logistic 
regression, meta-analyses, and pooled-effect estimates. Models were stratified by age at diagnosis 
(infants <1 year-old vs. children 1-14 years-old) and by study design, using five-year parental age 
increments and controlling for sex, ethnicity, birthweight, prematurity, multiple gestation, birth 
order, maternal smoking and education, age at diagnosis (cases aged 1-14 years), and recruitment 
time period.
Results: Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) derived from RCC, but 
not from the QCC, studies showed a higher AML risk for infants of mothers ≥40-year-old (OR = 
6.87; 95% CI: 2.12-22.25). There were no associations observed between any other maternal or 
paternal age group and AML risk for children older than one year.
Conclusions: An increased risk of infant AML with advanced maternal age was found using 
data from RCC, but not QCC studies; no parental age-AML associations were observed for older 
children.
Keywords
infant acute myeloid leukemia; childhood cancer; epidemiology; maternal age; paternal age; risk 
factors
INTRODUCTION
Acute myeloid leukemia (AML) is very rare in children accounting for about 15% of all 
childhood leukemia cases[1]. Its incidence varies significantly between and within countries, 
continents and ethnic groups[1,2]. This variability could be due to genetic, environmental[3] 
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or socioeconomic factors, although underascertainment of cases likely plays a role. AML 
incidence is higher in infants less than one year of age, dropping in childhood to gradually 
increase again in adolescents and yound adults[3]. Heterogeneity by disease subtype and 
biologic characteristics is noticeable, especially among infants[4].
Large collaborative studies have examined the association of AML with several potential 
risk factors such as demographic and genetic characteristics[3], socioeconomic indices[5], 
environmental exposures (e.g. solvents[6], ambient air pollution[7], pesticides[8]), 
vitamins[9], infections, and birth characteristics [including anthropometrics[10], gestational 
age[11], birth order, and method of delivery (vaginal vs. cesarean)[12]), with findings that 
vary across studies for most factors. In contrast, associations of genetic syndromes (i.e., 
Down syndrome, Fanconi anemia, Bloom syndrome) with AML have been well 
established[3], but explain only a small percentage of all cases.
Several studies have examined the association between parental age and increased risk of 
various types of childhood cancer[13,14,15,16], acute leukaemia[17,18] and infant AML[19] 
in particular, with inconsistent results. We sought to elucidate this association by using the 
largest existing individual-level AML dataset. Here we report combined analyses of data 
from 17 studies; 13 participating in the Childhood Leukemia International Consortium 
(CLIC) across nine countries in Europe, America, and New Zealand and another four non-
CLIC studies. To take into account the possible selection bias of some included case-control 
(CC) studies which required active participation[20], we analysed the data of registry-based 
case-control(RCC) studies separately from those of questionnaire-based case-control(QCC) 
studies.
METHODS
Study designs and availability of data
CLIC was established in 2007 to promote investigations on the association of childhood 
leukemia with rare exposures, gene-environment interactions through pooling of data from 
independent studies internationally. Thirteen CLIC studies provided data. In order to further 
increase the size of our data four non-CLIC registry-based studies were also included (US, 
California State, CCLRP; US, Minnesota State; US, New York State; US, Texas State) and 
provided individual-level data from large-scale record-linkage of national or statewide 
population-based administrative registries. Overall, seven registry-based CC and 10 
questionnaire-based CC studies were included in this pooling project. Of note, some of the 
questionnaire-based CC studies involve also subjects from population-based registries, at 
least with regards to case recruitment.
Adjusted summary estimates were provided by the California State registry-based CC study, 
whereas three State cancer registries (Minnesota, New York -excluding New York City-, 
Texas) provided pooled analysis-derived estimates (Supplementary Table 1). Questionnaire-
based CC studies conducted in Brazil, Costa Rica, Germany, Greece, Italy, New Zealand, 
UK, and the U.S. (California State, COG-E14, Texas State) provided individual-level data on 
the exposures of interest for cases and controls and disease-related information. The term 
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QCC studies refers to the method of data collection via questionnaire and includes 
interview-based studies. Details on data collection for each study are reported elsewhere[21].
The age range of cases and controls at diagnosis or recruitment was 0-14 years. Children 
with Down syndrome –known to be associated with advanced maternal age- and an 
established strong risk factor for the development of leukemia[22,23] - were excluded from 
these analyses from both cases and controls, especially because this was an exclusion 
criterion for control enrollment in some studies.
Data collection and harmonization
Variables contributed by the individual studies were reviewed and harmonized. Whenever 
controls were frequency-matched on age [Brazil, Costa Rica, Denmark, Germany, New 
Zealand, Texas CC study, and the five RCC studies from the U.S.(States of California, 
Minnesota, New York, Texas, and Washington)], a maximum of three controls per case were 
randomly selected. Percentages of missing values for each variable per study were mostly 
small (Supplementary Table 2). For Denmark and Finland where ethnicity was not available, 
the data provider assigned the category Caucasian whereas for Costa Rica the category non-
Caucasian was used.
Statistical analyses
Associations of childhood AML with paternal and maternal age were first examined using 
cubic spline models for each study with individual-level data but results were inconsistent 
across studies. Based on two recent publications[17,19] in order to explore the impact of 
extremely young and very advanced parental ages, six age categories were defined (<20, 
20-24, 25-29 [reference], 30-34, 35-39, ≥40 years) for maternal and paternal age.
Covariates included in the multivariable models were literature-derived, determined a priori, 
and categorized as follows: index child’s age at diagnosis (<1, 1-4, 5-9, 10-14 years) (used 
as a covariate only for analyses among 1-14 year olds); sex (male/female); child’s ethnicity 
(Caucasian/non-Caucasian), birthweight (500g increments; lowest and highest recorded 
weights were 501 gr and 6001 gr respectively); maternal education (low: secondary 
education not completed, intermediate: secondary education completed, high: college, 
university or higher degree); maternal smoking during pregnancy (yes/no); preterm birth 
(gestational age <37 weeks: yes/no), multiple gestation (yes/no), birth order (1, 2, ≥3), and 
time period of diagnosis/recruitment (1968-1993, 1994-2003, 2004-2015). Paternal and 
maternal age variables were first included in the models separately and then simultaneously 
(i.e., mutual adjustment).
Risk estimates were calculated using maximally-adjusted logistic regression models. 
Because of the known different biological characteristics of infant AML, models were 
stratified by age at diagnosis (<1 year of age vs. 1-14 years) and also by study design (RCC 
vs. QCC) and analyses were conducted separately. Further analyses for AML in children <2 
years-old were also performed. Variables with >20% missing values were excluded from 
study-specific models [17]. Data from the 10 questionnaire-based CC studies were pooled 
using unconditional logistic regression models controlling for individual study. Meta-
analysis of individual study-effect estimates was not feasible in several CC studies due to 
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paucity of data for some of parental age groups for the analysis of infant AML cases (<1 
year-old). For the tabulated, registry-based case control, linkage-derived data meta-analysis 
was performed.
Among the seven registry-based CC studies, two effect estimates were supplied: one for the 
California State RCC study, a second for the combined effect estimate for Minnesota, New 
York and Texas States RCC studies. A third effect estimate was calculated from the pooled 
individual-level data for the remaining three registry-based CC studies (Washington State, 
Finland and Denmark). The three effect estimates were then combined using a random-
effects meta-analysis, with heterogeneity of the estimates tested using Cochran Q and I2 
statistic (statistical significance was set at p-value <0.10, derived from the Cochran Q test). 
The supplied effect estimates were adjusted for the same variables as those that we used in 
the raw data. Statistical analyses were conducted with SAS 9.4 version and STATA 14.1 
version.
RESULTS
Characteristics of the study population
A total of 3182 childhood (0-14 years) AML cases and 8377 controls were included in the 
analyses. The seven registry-based NCC studies contributed data for 1888 cases (285 
infants) and 6102 controls (922 infants); the 10 questionnaire-based CC studies contributed 
1294 cases (186 infants) and 2275 controls (402 infants). Enrollment periods of diagnosis or 
recruitment varied by study and spanned from 1968 to 2015. Characteristics of cases and 
controls stratified by age group (<1 year vs. 1-14 years) and by study design (RCC vs. QCC) 
are presented in Table 1. Differences in the distributions by sex, ethnicity, and time period at 
diagnosis in the infant dataset could be attributed to the differential distributions of these 
characteristics among subjects from Brazil, during the 1998-2015 period. When the 
Brazilian data were excluded (data not shown), the distributions became similar. Overall, 
boys outnumbered girls in the 1-14 year age group. Caucasians represented 65% and 73% of 
participants (cases and controls together) in RCC studies and QCC studies, respectively. The 
distribution of maternal and paternal age at childbirth of the controls was highly variable 
across studies (Supplementary Figure 1).
Results by study design
Table 2 shows the results from the meta-analysis of the RCC studies and the multivariable 
analysis of the QCC studies. The meta-analysis of RCC studies indicated an almost seven-
fold increase in AML risk for infants whose mothers were older than 40 years-old compared 
to infants whose mothers were 25-29 years-old (ORNCC =6.87, 95% CI=2.12-22.25 - 
adjusted for paternal age). An increased AML risk for infants whose mothers were 40 years-
old or older was also observed in the multivariable analysis of the QCC studies, but did not 
reach statistical significance and confidence intervals were wide (ORcc=3.31, 95% CI 
=0.64-16.98). None of the remaining maternal age groups were associated with AML risk 
neither among infants nor among older children. Analyses of the effect of paternal age 
showed no statistically significant associations with the risk for childhood AML in infants or 
older children.
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DISCUSSION
In this study, the effect of parental age -a well-defined exposure variable- on the incidence of 
childhood AML was assessed using the largest dataset of newly diagnosed children with 
AML worldwide. A seven-fold increase in risk of AML before the age of one year was 
found for children born to mothers older than 40 years compared to mothers aged 25-29 
years. No association of paternal age with AML risk was found in RCC or QCC studies.
The association of childhood cancer and leukemia with parental age has been previously 
investigated [13,14,15]. It has been shown that advanced parental age is associated with 
increased ALL risk in the offspring [17]. However, fewer studies have focused solely on the 
risk of AML. Recently, Marcotte et al, studied this association and found that maternal age 
>40 years significantly increased the risk of infant AML (OR:4.8, 95%CI:1.8-12.76), 
whereas paternal age <20 years was associated with an increased risk of infant ALL 
(OR:3.69, 95%CI: 1.62-8.41)[19]. The size of the effect of advanced maternal age was 
similar to that in the present study. Moreover, despite the relatively high effect magnitude 
when using multiplicative measures of association, the absolute risk increase as well as the 
derived attributable fractions remain small.
Similarly, in a recent study by Sergentanis et al, maternal age was found to be significantly 
associated with an increased risk of childhood AML in a U-shaped manner as both oldest 
(>40 years) and youngest (<20 years) ages were associated with a 23% increase in AML 
risk[18]. Also in these analyses, only fathers in the youngest age-group had a 28% increase 
in risk of having a child with AML[18]. In contrast to the study by Sergentanis et al, where 
results derived from the meta-analysis of 77 published case-control studies, in the current 
analysis, the participating studies contributed individual-level data which allowed more 
detailed analyses with simultaneous adjustment for maternal and paternal age. It also 
allowed subgroup analyses by age at diagnosis, which proved to be particularly important 
given the striking association of infant AML with advanced maternal age that emerged. The 
fact that the association of younger paternal age with AML reported by Sergentanis et al. 
was not replicated in the present study, could be attributed to methodological differences 
such as the use of data from RCC studies and not QCC studies which require active 
participation, the use of adjusted estimates, and the availability of primary data regarding 
age.
The association of advanced maternal age with infant AML may be explained by several 
mechanisms. Infant leukemia is characterized by high prevalence of MLL gene 
rearrangements (50-80% of infant ALL and 34-50% of infant AML compared to 6% and 
14% in older children, respectively)[4,24,25]. In addition, secondary AML after 
chemotherapy with DNA topoisomerase-II inhibitors (e.g. epipodophyllotoxins) usually 
harbors a large number of MLL mutations[26]. It has been suggested that dietary exposure 
of pregnant women to naturally occurring topoisomerase-II inhibitors (e.g. in beans, fresh 
and canned vegetables, fruit, soy, coffee, tea, cocoa, and wine)[27] may contribute to the 
increased incidence of AML among their infants[28]. In the present study, no data on the 
MLL gene status of the cases were available, so it was not possible to assess this association. 
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Further research incorporating genetic information should be conducted to better elucidate 
associations of maternal and paternal age with MLL mutation status.
Other carcinogenic effects and de novo mutations, associated with advanced maternal age, 
could also be involved in the etiology of infant AML. In a study of MLL-negative infant 
leukemia, where whole genome sequencing was performed for infant-mother pairs, a high 
burden of germline genetic variation in the MLL3 gene was found[29]. More specifically, it 
was shown that 100% of infant AML and 50% of infant ALL cases were compound 
heterozygotes of MLL3[29]. Nearly half of the germline variation in the infants could be 
tracked to maternal alleles, and it was suggested that the additional germline variation was 
either of paternal or de novo origin or both[29].
The sizeable positive association of infant AML with advanced maternal age raises the 
question of the role of fertility treatments. Although, previous studies have demonstrated the 
association between assisted reproduction, especially in vitro fertilization, and early onset 
ALL, no association was found for AML[30,31]. Notably, ages at which women and men 
have their first offspring have increased over the last decades with a rising percentage of 
parents older than 40 years[32]. This increase in childbearing age could be potentially 
associated with increased frequency of de novo mutations[33,34], and decreased methylation 
levels in the offspring of older parents via the same mechanism that causes increased 
frequency of chromosomal abnormalities[35,36,37]. In this study, cases and controls with 
trisomy 21 were excluded from the analyses. Review of the data before exclusion revealed 
that the percentage of controls with Down syndrome was around the expected 0.1% which 
can be used as a robust indicator of completeness of registration.
In order to make better use of the available individual-level data and to reduce potentially 
biased findings, studies were grouped by study design (RCC vs. QCC) and analysed 
separately in the present study. In the methodologically less prone to bias, RCC a strong 
association between advanced maternal age and infant AML was observed, whereas no such 
association was found in children diagnosed at older ages. Self-reported information in 
questionnaire- or interview-based CC studies raise a concern for bias, as does the possibility 
that controls may not fully represent the underlying population since there is substantial 
potential for selection bias [20]. In RCC studies, this likelihood is diminished as controls are 
randomly selected from population registers, and may better represent the source population 
from which cases rose. This strength may also help explain why the associations with 
maternal age differed between the two types of study.
In the current analyses, it was not possible to determine how well the variable “parental age” 
(recorded in RCC studies or reported in QCC studies) reflected the age of the biological 
parents at the time of birth of the index child and not the age of the legal guardians. 
However, as adoption is rare (e.g. 0.6% in the nationwide Danish study), it is not anticipated 
that non-availability of the age of the biological parents would have affected our 
findings[15]. In addition, in the Washington State RCC study, the biological parent’s age is 
recorded even in the case of adoption, whereas in the UKCC and the CCLS California 
studies adopted children are not included unless the biological parents are available for 
interview. Therefore, this type of misclassification is unlikely. Finally, as the median rate of 
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paternal discrepancy (when a child is identified as being biologically fathered by someone 
other than the man who believes he is the father) is low (3.7% internationally) any 
misclassification of paternal age would likely have a negligible effect[38].
The variability in the distribution of parental age of controls between countries could have 
possibly introduced some unmeasurable error. In Greece, for example, the maternal age 
distribution among controls seemed to follow the national estimates, but there are no 
national statistics on the paternal age distribution. Likewise, the parental age distribution in 
the Italian study (SETIL) followed the national population pattern and seemed to yield 
results similar to those of a cohort study[39]. Finally, to eliminate the potential effect of 
collinearity between maternal and paternal age, the two variables were mutually adjusted for. 
Although the roles of maternal and paternal age cannot be easily disentangled our analysis 
has demonstrated that advanced maternal age is by it’s own right a significant risk factor for 
infant AML.
The very large volume of primary data of AML cases that have been compiled from all the 
participating CLIC and non-CLIC studies is one of this study’s main strenghts. Although 
several studies have examined the association of parental age with leukemia [13–17,39] and 
the interplay with other possible factors like birth order[40] the numbers are small for AML. 
For infant AML, in particular they are even smaller. Another strength is the use of 
population-based health records’ linkage in the RCC studies which aimed at reducing a 
potential selection bias that might have affected the participating QCC studies which seem to 
be more vulnerable since participation of controls is often affected by parental and more 
specifically paternal age[20].
Information on MLL rearrangement status, use of assisted reproductive technologies, and 
AML subtypes (M0-7) was not collected by most of the participating studies; therefore, no 
conclusions on the biological mechanisms underlying the association of advanced maternal 
age and infant AML could be reached. Additional limitations of the present analyses include 
differences in data collection methodology for cases and controls by country, as well as the 
prolonged and variable data collection periods for each study.
In conclusion, advanced maternal age was found to be associated with AML in infants but 
not in other age-groups. Extremely young or advanced paternal age was not associated with 
AML in any age group. Inclusion of genetic information in future studies will further 
elucidate the mechanisms that underlie the observed association and to achieve this 
international collaboration is required.
Supplementary Material
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Abbreviations:
AML acute myeloid leukemia
ALL acute lymphoblastic leukemia
CLIC Childhood Leukemia International Consortium
RCC registry-based case-control study
QCC questionnaire-based case-control study
CI confidence interval
OR Odds ratios
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Table 1.
Characteristics of acute myeloid leukemia (AML) cases and controls by study design and age at diagnosis (<1 
year, 1-14 years)
Age at diagnosis
<1 year 1-14 years
Study 
design →
Registry-based CCa (no of 
studies=7)
Questionaire-based CC (no 
of studies =10)
Registry-based CC (no of 
studies =7)
Questionaire-based CC (no 
of studies =10)
AML cases 
N=285
Controls 
N=922
AML cases 
N=186
Controls 
N=402
AML cases 
N=1603
Controls 
N=5180
AML cases 
N=1108
Controls 
N=1873
Variables ↓ N % N % N % N % N % N % N % N %
Index child’s age at diagnosis/recruitment 
(years)
<1 285 100.0 922 100.0 186 100.0 402 100.0
1-4 766 47.8 2468 47.7 456 41.2 814 43.5
5-9 389 24.3 1260 24.3 331 29.9 579 30.9
10-14 448 27.9 1452 28.0 321 28.9 480 25.6
Index 
child’s sex
Male 131 46.0 423 45.9 100 53.8 243 60.5 836 52.2 2719 52.5 595 53.7 977 52.2
Female 154 54.0 499 54.1 86 46.2 159 39.5 767 47.8 2461 47.5 513 46.3 896 47.8
Time period at diagnosis/
recruitment
1968-1993 96 33.7 297 32.2 67 36.0 110 27.4 493 30.8 1551 29.9 508 45.9 785 41.9
1994-2003 122 42.8 400 43.4 62 33.3 216 53.7 725 45.1 2356 45.5 390 35.2 821 43.8
2004-2015 67 23.5 225 24.4 57 30.7 76 18.9 387 24.1 1273 24.6 210 18.9 267 14.3
Index 
child’s race
Caucasian 181 63.5 576 62.6 149 80.1 266 66.2 1072 67.0 3395 65.6 823 74.4 1367 73.0
Non-
Caucasian 104 36.5 344 37.4 37 19.9 136 33.8 529 33.0 1779 34.4 283 25.6 505 27.0
Missing 0 0.0 2 0.2 0 0.0 0 0.0 2 0.1 6 0.1 2 0.2 1 0.1
Birthweight 
(g)
<2500 23 8.2 48 5.3 7 3.8 43 10.9 93 6.0 264 5.2 55 5.1 126 6.9
2500-2999 44 15.8 133 14.6 32 17.5 89 22.5 234 15.1 742 14.7 182 16.7 316 17.3
3000-3499 102 36.5 323 35.5 60 32.8 131 33.1 514 33.2 1784 35.5 368 33.8 670 36.6
3500-3999 78 28.0 287 31.6 66 36.1 105 26.5 489 31.6 1567 31.2 336 30.8 533 29.1
≥4000 32 11.5 118 13.0 18 9.8 28 7.0 219 14.1 673 13.4 148 13.6 184 10.1
Missing 6 2.1 13 1.4 3 1.6 6 1.5 54 3.4 150 2.9 19 1.7 44 2.4
Maternal 
educationb
Low 42 17.4 118 14.6 42 22.8 130 32.4 170 15.5 503 14.2 294 26.8 520 28.1
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Age at diagnosis
<1 year 1-14 years
Study 
design →
Registry-based CCa (no of 
studies=7)
Questionaire-based CC (no 
of studies =10)
Registry-based CC (no of 
studies =7)
Questionaire-based CC (no 
of studies =10)
AML cases 
N=285
Controls 
N=922
AML cases 
N=186
Controls 
N=402
AML cases 
N=1603
Controls 
N=5180
AML cases 
N=1108
Controls 
N=1873
Variables ↓ N % N % N % N % N % N % N % N %
Intermediate 131 54.4 462 57.1 97 52.7 210 52.4 655 59.6 2121 59.6 589 53.8 933 50.4
High 68 28.2 229 28.3 45 24.5 61 15.2 274 24.9 933 26.2 212 19.4 398 21.5
Missing 44 15.4 113 12.3 2 1.1 1 0.3 504 31.4 1623 31.3 13 1.2 22 1.2
Maternal smoking during 
pregnancy
No 156 92.9 536 95.0 150 81.1 297 74.2 721 92.7 2373 92.3 856 77.9 1437 77.1
Yes 12 7.1 28 5.0 35 18.9 103 25.8 57 7.3 199 7.7 243 22.1 428 22.9
Missing 117 41.1 358 38.8 1 0.5 2 0.5 825 51.5 2608 50.3 9 0.8 8 0.4
Preterm 
birthc
No 223 86.1 772 91.6 135 91.8 208 92.9 1287 89.0 4318 91.6 908 94.1 1440 92.9
Yes 36 13.9 71 8.4 12 8.2 16 7.1 159 11.0 394 8.4 57 5.9 110 7.1
Missing 26 9.1 79 8.6 39 21.0 178 44.3 157 9.8 468 9.0 143 12.9 323 17.3
Multiple 
pregnancy
No 266 97.4 865 97.6 176 96.7 385 97.5 1460 98.1 4709 97.4 1046 98.9 1695 97.7
Yes 7 2.6 21 2.4 6 3.3 10 2.5 28 1.9 124 2.6 12 1.1 39 2.3
Missing 12 4.2 36 3.9 4 2.2 7 1.7 115 7.2 347 6.7 50 4.5 139 7.4
Birth order
1 111 39.2 370 40.3 81 44.2 174 46.6 599 38.0 2065 40.4 491 45.2 777 44.9
2 82 29.0 315 34.3 64 35.0 107 28.7 528 33.4 1705 33.3 356 32.8 584 33.8
≥3 90 31.8 233 25.4 38 20.8 92 24.7 451 28.6 1343 26.3 239 22.0 368 21.3
Missing 2 0.7 4 0.4 3 1.6 29 7.2 25 1.6 67 1.3 22 2.0 144 7.7
Maternal age at 
birth (years)
<20 30 10.5 62 6.7 15 8.1 51 12.8 139 8.6 431 8.3 110 10.0 170 9.2
20-24 57 20.1 196 21.3 38 20.6 99 24.8 375 23.4 1267 24.5 285 25.9 449 24.2
25-29 73 25.7 307 33.3 59 31.9 134 33.6 503 31.4 1640 31.7 373 33.9 613 33.0
30-34 69 24.3 229 24.8 47 25.4 78 19.5 365 22.8 1229 23.7 237 21.5 435 23.4
35-39 36 12.7 109 11.8 20 10.8 31 7.8 179 11.2 507 9.8 84 7.6 162 8.7
≥40 19 6.7 19 2.1 6 3.2 6 1.5 42 2.6 106 2.0 12 1.1 27 1.5
Missing 1 0.4 0 0 1 0.5 3 0.8 0 0.0 0 0.0 7 0.6 17 0.9
Mean ± SD 28.5±6.79 28.1±5.66 27.9±6.09 26.4±5.84 27.6±5.99 27.4±5.73 26.8±5.53 27.2±5.66
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Age at diagnosis
<1 year 1-14 years
Study 
design →
Registry-based CCa (no of 
studies=7)
Questionaire-based CC (no 
of studies =10)
Registry-based CC (no of 
studies =7)
Questionaire-based CC (no 
of studies =10)
AML cases 
N=285
Controls 
N=922
AML cases 
N=186
Controls 
N=402
AML cases 
N=1603
Controls 
N=5180
AML cases 
N=1108
Controls 
N=1873
Variables ↓ N % N % N % N % N % N % N % N %
Paternal age at 
birth (years)
<20 9 3.3 25 2.8 7 3.9 14 3.7 44 2.9 163 3.2 40 3.9 34 2.0
20-24 43 15.8 131 14.3 26 14.4 75 19.6 250 16.2 896 17.5 169 16.2 303 17.4
25-29 69 25.4 255 27.9 45 25.0 110 28.7 452 29.4 1512 29.5 321 30.8 503 28.9
30-34 72 26.5 256 28.0 50 27.8 103 26.9 415 27.0 1407 27.5 276 26.5 495 28.5
35-39 40 14.7 160 17.5 33 18.3 53 13.8 246 16.0 763 14.9 165 15.8 257 14.8
≥40 39 14.3 87 9.5 19 10.6 28 7.3 131 8.5 379 7.4 71 6.8 147 8.4
Missing 13 4.6 8 0.9 6 3.2 19 4.7 65 4.1 60 1.2 66 6.0 134 7.2
Mean ± SD 31.3±7.40 30.8±6.67 31.0±7.55 29.8±6.57 30.3±6.55 30.1±6.52 30.0±6.70 30.4±6.55
aCC: Case control;
b
Maternal education: Low: secondary education not completed; intermediate: secondary education completed; high: college, university or higher 
degree;
c
Preterm birth: Yes: gestational age <37 weeks; No: gestational age ≥37 weeks
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Table 2.
Association of maternal and paternal age with the risk of childhood (0–14 years) acute myeloid leukemia 
(AML): Meta-analysis derived Odds Ratios (OR) and 95% Confidence Intervals (95% CI) of the registry 
based case-control (RCC) studies and multiple logistic regression derived ORs of pooled data of the 
questionnaire based case-control (QCC) studies; maternal and paternal age are both adjusted for in the models.
Design→
Variable↓
<1 year 1-14 years
RCC studiesa QCC studiesb RCC studiesa QCC studiesb
AML 
cases 
N
Controls 
N
OR (95% 
CI)
AML 
cases 
N
Controls 
N
OR (95% 
CI)
AML 
cases 
N
Controls 
N
OR (95% 
CI)
AML 
cases 
N
Controls 
N
OR (95% 
CI)
Maternal 
age 
(years)
<20 23 62 1.44 (0.65-3.20) 12 44
0.47 
(0.16-1.34) 112 399
0.93 
(0.55-1.59)c 96 114
1.21 
(0.81-1.80)
20-24 54 185 1.13 (0.70-1.82) 35 80
1.01 
(0.54-1.86) 344 1202
0.92 
(0.62-1.38)c 256 382
1.04 
(0.82-1.33)
25-29 69 298 Reference 55 123 Reference 463 1579 Reference 343 517 Reference
30-34 66 229 1.53 (0.81-2.88) 45 74
1.23 
(0.69-2.17) 351 1183
0.98 
(0.83-1.17) 220 380
0.82 
(0.64-1.05)
35-39 35 106 2.01 (0.78-5.20) 20 26
1.46 
(0.63-3.35) 173 499
1.14 
(0.90-1.44) 76 142
0.75 
(0.52-1.08)
≥40 19 18 6.87 (2.12-22.25) 5 3
3.31 
(0.64-16.98) 39 103
1.26 
(0.56-2.81)c 9 25
0.52 
(0.22-1.19)
Paternal 
age 
(years)
<20 8 25
0.86 
(0.29-2.62)d 7 13
2.33 
(0.62-8.78) 44 162
0.91 
(0.60-1.38) 37 29
1.62 
(0.90-2.91)
20-24 43 128 1.16 (0.68-1.98) 23 65
1.11 
(0.54-2.29) 237 841
1.01 
(0.75-1.36) 161 267
0.81 
(0.61-1.07)
25-29 68 248 Reference 42 104 Reference 432 1471 Reference 309 457 Reference
30-34 70 253 0.84 (0.45-1.56) 49 99
0.96 
(0.54-1.70) 402 1362
0.97 
(0.82-1.15) 269 446
0.96 
(0.76-1.21)
35-39 39 158 0.60 (0.26-1.42) 32 44
1.29 
(0.61-2.70) 243 740
1.04 
(0.84-1.29) 157 231
1.12 
(0.83-1.52)
≥40 38 86 0.85 (0.42-1.74) 19 25
1.21 
(0.52-2.83) 124 389
0.95 
(0.69-1.30) 67 130
0.86 
(0.58-1.27)
RCC: registry-based case control studies; QCC: questionnaire-based case control studies; AML: acute myeloid leukemia;
In bold: statistically significant results at 0.05 level.
a
Meta-analysis derived OR comprising (a) pooled OR of the raw data from Denmark, Finland and Washington State adjusted for Caucasian vs. 
non-Caucasian ethnicity, birth weight, birth order and study, (b) provided pooled OR for Minnesota, New York and Texas States adjusted for 
Caucasian vs. non-Caucasian ethnicity, birth weight, birth order, birth year and sex and (c) provided OR for the CCRLP California study adjusted 
for Caucasian vs. non-Caucasian ethnicity, birth weight, birth order, pre-term birth, multiple pregnancy and study period.
b(Applies only to the 1-14 years-old study group) Pooled Odds Ratios, maximally adjusted for age (categorical; 1-4 [reference], 5-9, 10-14 years), 
sex, Caucasian vs. non-Caucasian ethnicity, birth weight, birth order, maternal education, maternal smoking during pregnancyand study.
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c
Meta-analyses with statistically significant heterogeneity: maternal age <20: I2:60.9% p=0.08; maternal age 20-24: I2:78.8% p=0.01; maternal 
age 40+: I2:66.1% p=0.05
d
Based on the meta-analysis of the CCRLP California study OR and the provided pooled OR for the Minnesota, New York, and Texas States 
studies
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